Fig 1: MiR-129-5p inhibition facilitated the malignant phenotypes of propofol-treated CC cells by targeting RPL14. Inhibitor NC, miR-129-5p inhibitor, miR-129-5p inhibitor+si-NC or miR-129-5p inhibitor+si-RPL14 was transfected into HeLa and SiHa cells before 10 µg/mL propofol exposure. (A and B) The mRNA and protein levels of RPL14 in HeLa and SiHa cells were detected by qRT-PCR assay and Western blot assay, respectively. (C–F) The colony formation, apoptosis, invasion and migration capacities of HeLa and SiHa cells were assessed by colony formation assay, flow cytometry analysis, transwell assay and wound healing assay, respectively. (G) The protein levels of MMP9, PCNA and Bax in HeLa and SiHa cells were measured via Western blot assay. **P<0.01, ***P<0.001.
Fig 2: Propofol suppressed tumor growth of CC in vivo. The nude mice were divided 4 groups: Model, Propofol, Propofol+vector and Propofol+oe-HOTAIR. (A) Tumor volume was monitored at 0 d, 5 d, 10 d, 17 d, 24 d, 31 d and 38 d. (B) Tumor weight was examined on day 38. (C) The levels of HOTAIR, miR-129-5p and RPL14 in the harvested tumors were detected by qRT-PCR assay. (D) The protein levels of MMP9, PCNA, Bax and RPL14 in the harvested tumors were measured by Western blot assay. *P<0.05, ***P<0.001.
Fig 3: Validation of plasma exosomal proteins RPL13 and RPL14 in independent cohorts. (A) The expression levels of RPL13 and RPL14 were detected by western blot in plasma exosome samples from 18 CML-R and 18 CML-S patients. TSG101 serves as an internal control for equivalent amounts of protein (15 μg). (B, C) The scatter diagram shown the quantified data of RPL14 (B) and RPL13 (C), respectively. CML-S, imatinib-sensitive chronic myeloid leukemia patients; CML-R, imatinib-resistant chronic myeloid leukemia patients. **p < 0.01, ***p < 0.001.
Fig 4: HOTAIR overexpression sponged miR-129-5p to modulate RPL14 expression in CC cells. (A–D) After HeLa and SiHa cells were transfected with vector, oe-HOTAIR, oe-HOTAIR+mimic NC or oe-HOTAIR+miR-129-5p mimic, the mRNA and protein levels of RPL14 were examined by qRT-PCR assay and Western blot assay, respectively. **P<0.01, ***P<0.001.
Fig 5: RPL14 acted as the target gene of miR-129-5p. (A and B) The mRNA and protein levels of RPL14 in different doses of propofol-treated HeLa and SiHa cells were detected by qRT-PCR assay and Western blot assay, respectively. (C) The predicted complementary sequences between miR-129-5p and RPL14. (D) The interaction between miR-129-5p and RPL14 was investigated by dual-luciferase reporter assay. (E) The interaction between miR-129-5p and RPL14 was verified by RIP assay. *P<0.05, **P<0.01, ***P<0.001.
Supplier Page from Abcam for Anti-RPL14 antibody [EPR12301]